MENU
+Compare
IMAB
Stock ticker: NASDAQ
AS OF
Aug 22 closing price
Price
$5.09
Change
+$0.38 (+8.07%)
Capitalization
415.65M

IMAB I-MAB Forecast, Technical & Fundamental Analysis

I-MAB is a clinical-stage biotech company... Show more

IMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for IMAB with price predictions
Aug 22, 2025

IMAB's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for IMAB turned positive on August 01, 2025. Looking at past instances where IMAB's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 01, 2025. You may want to consider a long position or call options on IMAB as a result. In of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

IMAB moved above its 50-day moving average on August 01, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for IMAB crossed bullishly above the 50-day moving average on August 01, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where IMAB advanced for three days, in of 236 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for IMAB moved out of overbought territory on August 19, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 42 cases where IMAB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMAB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IMAB broke above its upper Bollinger Band on August 14, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for IMAB entered a downward trend on July 31, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IMAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.096) is normal, around the industry mean (19.116). P/E Ratio (0.000) is within average values for comparable stocks, (55.025). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.643). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (16.978) is also within normal values, averaging (305.051).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
IMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

IMAB is expected to report earnings to fall 22.86% to -5 cents per share on November 13

I-MAB IMAB Stock Earnings Reports
Q3'25
Est.
$-0.05
Q2'25
Missed
by $0.03
Q1'25
Beat
by $0.09
Q4'24
Est.
$-0.06
Q3'24
Missed
by $0.04
The last earnings report on August 20 showed earnings per share of -7 cents, missing the estimate of -3 cents. With 3.48M shares outstanding, the current market capitalization sits at 415.65M.
A.I. Advisor
published General Information

General Information

a clinical stage biopharmaceutical company, which engages in developing and commercialization of differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
555 West Haiyang Road
Phone
+86 2160578000
Employees
318
Web
https://www.i-mabbiopharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VSMVX395.6116.09
+4.24%
Vanguard S&P Small-Cap 600 Val Idx Instl
PCSVX17.910.63
+3.65%
PACE Small/Medium Co Value Equity P
FGRAX51.800.74
+1.45%
Franklin Growth Opportunities A
LIRRX10.030.14
+1.42%
Lord Abbett International Value R3
FMIEX10.860.10
+0.93%
Wasatch Global Value Investor

IMAB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, IMAB has been loosely correlated with VCYT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if IMAB jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMAB
1D Price
Change %
IMAB100%
+8.07%
VCYT - IMAB
43%
Loosely correlated
+5.33%
INDP - IMAB
39%
Loosely correlated
+2.65%
ARRY - IMAB
31%
Poorly correlated
+8.10%
ALT - IMAB
30%
Poorly correlated
+0.28%
AXON - IMAB
29%
Poorly correlated
+0.36%
More